Posted on by Leave a Comment on Pilar Giraldo – Medical field – Lifetime achievement Award
72 / 100
Powered by Rank Math SEO

Pilar Giraldo – Medical field – Lifetime achievement Award

Dr. Pilar Giraldo distinguished academic and researcher in the field Identification of patient-reported outcome measures and patient-reported experience measures in Gaucher disease in Spain. Dr. Pilar Giraldo Castellano appears highly suitable for the Research for Lifetime Achievement Award based on her extensive contributions and accomplishments in the field of hematology, particularly focusing on rare diseases.

🌐 Professional Profile

Educations📚📚📚

  • PhD in Medicine and accredited as a Full Professor by ANECA.
  • Master’s in Research Methodology and Molecular Oncology.
  • Coordinator of Doctorate studies at University San Jorge.

  • Research and Publications:

    • Head of research group Unit 752 of the Center for Biomedical Research Network on Rare Diseases (CIBERER).
    • Published over 140 articles in peer-reviewed journals, more than 20 book chapters, and 5 monographs.
    • Holds 5 patents related to her field.

  • Leadership in Research Projects:

    • Principal Investigator in numerous significant projects, such as the National Plan project TED2021-131518B-C32.
    • Directed more than 20 doctoral theses.
    • Led various research initiatives focusing on lysosomal diseases and other hematological conditions.

  • International Recognition and Collaboration:

    • Organized national and international congresses, including the 12th EWGGD Congress in 2016.
    • Part of the Expert Committee of the IWGGD and the Task Force on GD of the EHA.
    • Collaborates extensively with international bodies and foundations.

  • Awards and Recognition:

    • Received multiple awards for her contributions and those of her research group members at national and international congresses.
    • Recognized for her innovative work in utilizing artificial intelligence and machine learning in medical research.

  • Teaching and Mentorship:

    • Directed numerous continuing education courses for physicians.

Created educational resources and has been involved in life-long learning activities.

📝🔬Publications📝🔬

  • Elstein D, Belmatoug N, Bembi B, Deegan P, Fernandez-Sasso D, Giraldo P,
    Göker-Alpan Ö, Hughes D, Lau H, Lukina E, Revel-Vilk S, Schwartz IVD, Istaiti M, Botha J,
    Gadir N, Schenk J, Zimran A; GOS Study Group. 2024. Twelve Years of the Gaucher
    Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global
    Patient Registry.J Clin Med.13-12.
  • Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N, Linhart
    A, Hughes DA, Hopkin RJ, Tøndel C, Langeveld M, Giraldo P, Pisani A, Germain DP, Mehta
    A, Deegan PB, Molnar MJ, Ortiz D, Jovanovic A, Muriello M, Barshop BA, Kimonis V,
    Vujkovac B, Nowak A, Geberhiwot T, Kantola I, Knoll J, Waldek S, Nedd K, Karaa A, BrillAlmon E, Alon S, Chertkoff R, Rocco R, Sakov A, Warnock DG.;. 2024. Head-to-head trial
    of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and
    deteriorating renal function: results from the 2-year randomised phase III BALANCE
    study. J Med Genet.21-61, pp.520-530.
  • Serrano-Gonzalo I, de Frutos LL, Lahoz-Gil C, Delgado-Mateos F, FernándezGalán MÁ, Morales-Conejo M, Calle-Gordo MV, Ibarretxe-Gerediaga D, MadinaveitiaOchoa A, Albarracin-Arraigosa A, Balanzat-Muñoz J, Correcher-Medina P, García-Frade LJ,
    Hernández-Rivas JM, Labbadia F, López-Dupla JM, Lozano-Almela ML, Mora-Casterá E,
    Noya-Pereira MS, Ruíz-Guinaldo MÁ, Del Mar Tormo-Díaz M, Vitoria-Miñana I, ArévaloVargas I, Andrade-Campos M, Giraldo P. Real life data: follow-up assessment on Spanish
    3
    Gaucher disease patients treated with eliglustat. TRAZELGA project.. 2023. Real life data:
    follow-up assessment on Spanish Gaucher disease patients treated with eliglustat.
    TRAZELGA project. Orphanet J Rare Dis.18-1.
  • Stanescu S, Correcher Medina P, Del Castillo FJ, Alonso Luengo O, Arto
    Millan LM, Belanger Quintana A, Camprodon Gomez M, Diez Langhetée L, Garcia Campos
    O, Matas Garcia A, Perez-Moreno J, Rubio Gribble B, Visa-Reñé N, Giraldo-Castellano P,
    O’Callaghan Gordo M. 2023. Clinical Outcomes of Patients with Chronic Neuropathic
    Form of Gaucher Disease in the Spanish Real-World Setting: A Retrospective
    Study.Biomedicines.11-10.
  • Linhart A, Dostálová G, Nicholls K, West ML, Tøndel C, Jovanovic A, Giraldo P,
    Vujkovac B, Geberhiwot T, Brill-Almon E, Alon S, Chertkoff R, Rocco R, Hughes. 2023.
    Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were
    previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.
    Orphanet J Rare Dis. 18-1, pp.332.
  • Louw VJ, Fraser I, Giraldo P 2023. Management goals of type 1 Gaucher
    disease in South Africa: An expert Delphi consensus document on good clinical
    practice.PLoS One. 18-8.
  • Esther Valero Tena; Mercedes Roca Espiau; Jose Verdu Diaz; Jordi Diaz
    Manera; Marcio Andrade Campos; Pilar Giraldo Castellano. 2023. Advantages of digital
    technology in the assessment of bone marrow involvement in Gaucher’s disease. Front Med
    (Lausanne).
Pilar Giraldo – Medical field – Lifetime achievement Award

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *